Eledon Pharmaceuticals (ELDN) Competitors $2.68 +0.10 (+3.88%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$2.68 +0.00 (+0.19%) As of 09/9/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELDN vs. RZLT, RLAY, IMTX, MRVI, KROS, TERN, TRML, SIGA, PVLA, and IVAShould you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Rezolute (RZLT), Relay Therapeutics (RLAY), Immatics (IMTX), Maravai LifeSciences (MRVI), Keros Therapeutics (KROS), Terns Pharmaceuticals (TERN), Tourmaline Bio (TRML), Siga Technologies (SIGA), Palvella Therapeutics (PVLA), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry. Eledon Pharmaceuticals vs. Its Competitors Rezolute Relay Therapeutics Immatics Maravai LifeSciences Keros Therapeutics Terns Pharmaceuticals Tourmaline Bio Siga Technologies Palvella Therapeutics Inventiva Rezolute (NASDAQ:RZLT) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Which has better valuation & earnings, RZLT or ELDN? Rezolute is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRezoluteN/AN/A-$68.46M-$1.15-7.03Eledon PharmaceuticalsN/AN/A-$36.18M-$1.17-2.29 Is RZLT or ELDN more profitable? Rezolute's return on equity of -70.09% beat Eledon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets RezoluteN/A -70.09% -63.08% Eledon Pharmaceuticals N/A -92.51%-38.31% Do institutionals & insiders believe in RZLT or ELDN? 83.0% of Rezolute shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 18.4% of Rezolute shares are held by company insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor RZLT or ELDN? In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than Rezolute. MarketBeat recorded 11 mentions for Eledon Pharmaceuticals and 8 mentions for Rezolute. Rezolute's average media sentiment score of 1.03 beat Eledon Pharmaceuticals' score of 0.26 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eledon Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, RZLT or ELDN? Rezolute has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Do analysts recommend RZLT or ELDN? Rezolute currently has a consensus price target of $11.67, indicating a potential upside of 44.39%. Eledon Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 273.13%. Given Eledon Pharmaceuticals' higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Rezolute.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rezolute 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Eledon Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryRezolute beats Eledon Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELDN vs. The Competition Export to ExcelMetricEledon PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$154.49M$3.17B$5.83B$10.00BDividend YieldN/A2.28%5.28%4.53%P/E Ratio-2.2921.3475.6926.28Price / SalesN/A471.32544.78188.18Price / CashN/A45.5837.2059.76Price / Book2.5510.0511.506.41Net Income-$36.18M-$53.33M$3.28B$270.56M7 Day Performance3.47%1.39%1.42%3.13%1 Month Performance-1.11%11.91%11.28%9.74%1 Year Performance1.13%13.21%59.03%28.17% Eledon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELDNEledon Pharmaceuticals2.1626 of 5 stars$2.68+3.9%$10.00+273.1%+8.5%$154.49MN/A-2.2910RZLTRezolute3.0768 of 5 stars$7.12-1.4%$12.50+75.6%+52.2%$619.41MN/A-6.1940RLAYRelay Therapeutics2.8073 of 5 stars$3.59-2.7%$17.08+375.9%-57.2%$618.96M$10.01M-1.84330IMTXImmatics2.1232 of 5 stars$5.09-3.6%$14.67+188.1%-52.5%$618.69M$168.65M-7.83260Positive NewsHigh Trading VolumeMRVIMaravai LifeSciences3.5612 of 5 stars$2.42+1.7%$5.22+115.7%-70.0%$617.98M$259.18M-1.78610Positive NewsKROSKeros Therapeutics3.2928 of 5 stars$15.21-0.3%$30.00+97.2%-70.8%$617.76M$3.55M49.07100Positive NewsTERNTerns Pharmaceuticals3.9164 of 5 stars$6.96-1.6%$15.63+124.5%-17.2%$609.08MN/A-6.6940News CoveragePositive NewsAnalyst RevisionTRMLTourmaline Bio1.3686 of 5 stars$23.40+1.6%$50.14+114.3%+171.0%$601.20MN/A-6.8244Trending NewsAnalyst ForecastGap UpSIGASiga Technologies1.8698 of 5 stars$8.39+2.2%N/A+9.9%$600.77M$138.72M7.4240Positive NewsPVLAPalvella Therapeutics2.3629 of 5 stars$54.15+5.6%$58.50+8.0%N/A$598.88M$42.81M-4.48N/AAnalyst ForecastIVAInventiva2.9857 of 5 stars$6.19-2.5%$13.00+110.0%+143.6%$592.15M$9.95M0.00100Gap DownHigh Trading Volume Related Companies and Tools Related Companies RZLT Competitors RLAY Competitors IMTX Competitors MRVI Competitors KROS Competitors TERN Competitors TRML Competitors SIGA Competitors PVLA Competitors IVA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELDN) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWall Street Legend Issues Urgent AI Stock WarningChaikin's stepping forward with a new warning – focused on the red-hot A.I. frenzy taking the U.S. stock marke...Chaikin Analytics | SponsoredUnlock Friday's Full Potential: Two Simple Sentences that put profits in investors’ pocketsMost traders stick to the same routine each week. But a little-known market strategy has quietly delivered a 9...Eagle Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELDN Stock Alerts